Lechner D, Wiener C, Weltermann A, Eischer L, Eichinger S, Kyrle P A
Department of Medicine I, Medical University of Vienna, Vienna, Austria.
J Thromb Haemost. 2008 Aug;6(8):1269-74. doi: 10.1111/j.1538-7836.2008.02998.x. Epub 2008 Apr 26.
The pathogenesis and natural course of idiopathic upper extremity deep vein thrombosis (UEDVT) are unclear.
To compare patients with UEDVT and with idiopathic lower extremity deep vein thrombosis (LEDVT) regarding risk factors and recurrence.
We followed 50 patients with first idiopathic UEDVT and 841 patients with first idiopathic LEDVT for an average of 59 and 46 months, respectively. We excluded patients with natural inhibitor deficiency, lupus anticoagulant, cancer, pregnancy, isolated pulmonary embolism (PE), or long-term antithrombotic treatment. The endpoint was recurrent venous thromboembolism (VTE).
In comparison to LEDVT patients, UEDVT patients were younger (38 +/- 13 years vs. 49 +/- 16 years, P < 0.001), slimmer (body mass index: 24 +/- 4 vs. 27 +/- 5, P < 0.001), less frequently had a family history of VTE (18% vs. 31%, P = 0.06) or concomitant PE (8% vs. 31%, P =0.001), were less frequently carriers of factor V Leiden (12% vs. 30%, P = 0.009), and had lower thrombin generation marker levels (D-dimer, 283 +/- 361 ng mL(-1) vs. 456 +/- 446 ng mL(-1), P < 0.001; peak thrombin, 298 +/- 101 nm vs. 363 +/- 111 nm, P = 0.001). Recurrence occurred in two of 50 patients with UEDVT (4%) and in 129 of 841 patients with LEDVT (15%). After 5 years, the likelihood of recurrence was 2% [95% confidence interval (CI) 0-6] among UEDVT patients and 19% (95% CI 16-22; P = 0.02) among LEDVT patients. As compared to LEDVT patients, the adjusted risk of recurrence was 0.26 (95% CI 0.06-1.05; P = 0.059) in UEDVT patients.
The pathogenesis and natural course of the disease differ between patients with idiopathic UEDVT and LEDVT.
特发性上肢深静脉血栓形成(UEDVT)的发病机制和自然病程尚不清楚。
比较特发性UEDVT患者和特发性下肢深静脉血栓形成(LEDVT)患者的危险因素和复发情况。
我们分别对50例首发特发性UEDVT患者和841例首发特发性LEDVT患者进行了平均59个月和46个月的随访。我们排除了存在天然抑制剂缺乏、狼疮抗凝物、癌症、妊娠、孤立性肺栓塞(PE)或长期抗血栓治疗的患者。终点为复发性静脉血栓栓塞(VTE)。
与LEDVT患者相比,UEDVT患者更年轻(38±13岁对49±16岁,P<0.001),更瘦(体重指数:24±4对27±5,P<0.001),VTE家族史(18%对31%,P=0.06)或合并PE(8%对31%,P=0.001)的情况更少见,因子V Leiden携带者更少(12%对30%,P=0.009),凝血酶生成标志物水平更低(D-二聚体,283±361 ng/mL对456±446 ng/mL,P<0.001;凝血酶峰值,298±101 nM对363±111 nM,P=0.001)。50例UEDVT患者中有2例(4%)复发,841例LEDVT患者中有129例(15%)复发。5年后,UEDVT患者复发的可能性为2%[95%置信区间(CI)0-6],LEDVT患者为19%(95%CI 16-22;P=0.02)。与LEDVT患者相比,UEDVT患者调整后的复发风险为0.26(95%CI 0.06-1.05;P=0.059)。
特发性UEDVT和LEDVT患者的疾病发病机制和自然病程不同。